Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 28CNS 3Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Other 1NET 1Dermatologic 1

Conditions

Melanoma 3141Skin Neoplasms 554Lymphoma, T-Cell, Cutaneous 543Carcinoma, Non-Small-Cell Lung 421Neoplasms 388Mycosis Fungoides 369Breast Neoplasms 364Carcinoma, Basal Cell 360Keratosis, Actinic 335Sezary Syndrome 331Lymphoma, Non-Hodgkin 312Carcinoma, Renal Cell 308Neoplasm Metastasis 304Lymphoma 300Leukemia, Lymphocytic, Chronic, B-Cell 292Lymphoma, Large B-Cell, Diffuse 287Lymphoma, Follicular 286Hodgkin Disease 275Uveal Melanoma 274Lymphoma, B-Cell, Marginal Zone 273Lymphoma, Mantle-Cell 272Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Burkitt Lymphoma 258Lymphoma, Large-Cell, Immunoblastic 248Lung Neoplasms 236Colorectal Neoplasms 232Ovarian Neoplasms 214Lymphoma, Large-Cell, Anaplastic 206Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 203Multiple Myeloma 199

Interventions

LY2940680 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Diseases × Dermatologic × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡